Eagle Pharmaceuticals, Inc. Deferred Tax Assets, in Process Research and Development
Eagle Pharmaceuticals, Inc. had Deferred Tax Assets, in Process Research and Development of $7.58 million as of 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2023-03-23
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $7.58M.
- 2021-12-31: Deferred Tax Assets, in Process Research and Development $0.00.
- 2015-12-31: Deferred Tax Assets, in Process Research and Development $1.88M.
- 2014-12-31: Deferred Tax Assets, in Process Research and Development $2.26M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2022-12-31 | $7.58M 10-K · filed 2023-03-23 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
| 2015-12-31 | $1.88M 10-K · filed 2016-02-29 |
| 2014-12-31 | $2.26M 10-K · filed 2016-02-29 |
| 2014-09-30 | $2.35M 10-K · filed 2016-02-29 |
| 2013-09-30 | $2.57M 10-K · filed 2016-02-29 |